AJ Lanigan: Certainly. Actually, Pharma businesses are earning large dollars with treatment plans like Keytruda and Opdivo that deal with PD-1 and PD-L1. In this article’s the super interesting element: imagine checkpoints as targeted traffic indicators. You don’t want an immune system that’s jogging wild just like a freight coach waiting for link from Social Bookmarking (2)